FrancophonIA/ELRC3.0 huggingface dataset:
English: Depomedroxyprogesterone acetate (DMPA)/Efavirenz (150 mg IM single dose DMPA)
Spanish: Acetato de depomedroxiprogesterona (DMPA)/Efavirenz (dosis única de 150 mg IM de DMPA)
English: Each film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate).
Spanish: Cada comprimido recubierto con película contiene 600 mg de efavirenz, 200 mg de emtricitabina y 245 mg de tenofovir disoproxilo (como fumarato).
English: AUC: ↔ Cmax: ↑ 38% (↑ 14 to ↑ 67)
Spanish: AUC: ↔ Cmax: ↑ 38% (↑ 14 a ↑ 67)
English: In 35 patients receiving efavirenz 600 mg once daily, steady-state peak concentration (Cmax) was 12.9 ± 3.7 µM (29%) [mean ± standard deviation (S.D.) (coefficient of variation (%CV))], steady-state Cmin was 5.6 ± 3.2 µM (57%), and AUC was 184 ± 73 µM•h (40%).
Spanish: En los 35 pacientes que recibían 600 mg de efavirenz una vez al día, el pico de la concentración en estado estacionario (Cmax) fue de 12,9 ± 3,7 µM (29%) [media ± desviación estándar (D.S.) (coeficiente de variación (% C.V.
English: Common hypertriglyceridaemia3
Spanish: Frecuentes hipertrigliceridemia3
English: AUC: ↔ Cmax: ↓ 23% (↓ 30 to ↑ 16)
Spanish: AUC: ↔ Cmax: ↓ 23% (↓ 30 a ↑ 16)
English: Raltegravir/Emtricitabine
Spanish: Raltegravir/Emtricitabina
English: Valproic acid/Emtricitabine
Spanish: Ácido valproico/Emtricitabina
English: Sertraline/Emtricitabine
Spanish: Sertralina/Emtricitabina
English: Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
Spanish: (inducción de CYP3A4) La administración concomitante de efavirenz con atorvastatina, pravastatina o simvastatina no afectó a sus valores de AUC y Cmax.
English: Efavirenz levels may increase on stopping St. John's wort.
Spanish: Los niveles de efavirenz pueden incrementarse cuando se deje de tomar el hipérico.
English: Maraviroc/Emtricitabine
Spanish: Maraviroc/Emtricitabina
English: Norepinephrine and dopamine reuptake inhibitor Bupropion/Efavirenz [150 mg single dose (sustained release)/600 mg q.d.]
Spanish: Inhibidor de la recaptación de noradrenalina y dopamina Bupropión/Efavirenz (dosis única de 150 mg [liberación sostenida]/600 mg c/24 h)
English: There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, nelfinavir or ribavirin.
Spanish: No hubo interacciones farmacocinéticas clínicamente significativas cuando se administró concomitantemente tenofovir disoproxilo con emtricitabina, nelfinavir o ribavirina.
English: Buprenorphine/naloxone/Efavirenz
Spanish: Buprenorfina/naloxona/Efavirenz
English: General disorders and administration site conditions: Very common asthenia
Spanish: Trastornos generales y alteraciones en el lugar de administración: Muy frecuentes astenia
English: Atovaquone and proguanil hydrochloride/Emtricitabine
Spanish: Atovacuona y clorhidrato de proguanil/Emtricitabina
English: AUC: ↓ 83% (↓ 79 to ↓ 87) Cmax: ↓ 80% (↓ 77 to ↓ 83) Cmin: ↓ 86% (↓ 80 to ↓ 90)
Spanish: AUC: ↓ 83% (↓ 79 a ↓ 87) Cmax: ↓ 80% (↓ 77 a ↓ 83) Cmin: ↓ 86% (↓ 80 a ↓ 90)
English: Each Atripla film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate).
Spanish: Cada comprimido recubierto con película, de Atripla, contiene 600 mg de efavirenz, 200 mg de emtricitabina y 245 mg de tenofovir disoproxilo (como fumarato).
English: In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Spanish: Si es adecuado, deberá garantizarse la reanudación del tratamiento de la hepatitis B. No se recomienda interrumpir el tratamiento en pacientes con enfermedad hepática avanzada o cirrosis ya que la exacerbación post-tratamiento de la hepatitis puede provocar una descompensación hepática.
English: Raltegravir/Tenofovir disoproxil (400 mg b.i.d./-)
Spanish: Raltegravir/Tenofovir disoproxilo (400 mg c/12 h/-)
English: It is recommended that Atripla be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Spanish: Se recomienda la administración de Atripla con el estómago vacío, puesto que los alimentos pueden aumentar la exposición a efavirenz, lo que puede producir un aumento de la frecuencia de las reacciones adversas (ver las secciones 4.4 y 4.8).
English: Women of childbearing potential should undergo pregnancy testing before initiation of Atripla.
Spanish: Antes de iniciar el tratamiento con Atripla, las mujeres en edad fértil deben someterse a un test de embarazo.
English: AUC: ↓ 40% (↓ 26 to ↓ 57) Cmax: ↓ 18% (↓ 59 to ↑ 12)
Spanish: AUC: ↓ 40% (↓ 26 a ↓ 57) Cmax: ↓ 18% (↓ 59 a ↑ 12)
English: Posaconazole/Efavirenz (-/400 mg q.d.)
Spanish: Posaconazol/Efavirenz (-/400 mg c/24 h)
English: Co-administration of saquinavir/ritonavir and Atripla is not recommended.
Spanish: No se recomienda la administración concomitante de saquinavir/ritonavir y Atripla.
English: DMPA/Emtricitabine
Spanish: DMPA/Emtricitabina
English: If you do miss a dose of Atripla within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time.
Spanish: tómela tan pronto como pueda, y luego tome su dosis siguiente a su hora habitual.
English: AUC: ↑ 21% Cmin: ↑ 17%
Spanish: AUC: ↑ 21% Cmin: ↑ 17% Cmax: ↑ 15%
English: Fluoxetine/Emtricitabine
Spanish: Fluoxetina/Emtricitabina
English: Ethinyloestradiol/Tenofovir disoproxil (-/245 mg q.d.)
Spanish: Etinilestradiol/Tenofovir disoproxilo (-/245 mg c/24 h)
English: Carbamazepine/Emtricitabine
Spanish: Carbamazepina/Emtricitabina
English: Norgestimate/Ethinyloestradiol/ Emtricitabine
Spanish: Norgestimato/Etinilestradiol/ Emtricitabina
English: AUC: ↑ 21% (↑ 10 to ↑ 34) Cmax: ↑ 14% (↑ 4 to ↑ 26) Cmin: ↑ 25% (↑ 7 to ↑ 46)
Spanish: AUC: ↑ 21% (↑ 10 a ↑ 34) Cmax: ↑ 14% (↑ 4 a ↑ 26) Cmin: ↑ 25% (↑ 7 a ↑ 46)
English: - Medicines used to prevent organ transplant rejection (also called immunosuppressants),
Spanish: - Medicamentos utilizados para prevenir el rechazo de órganos tras su trasplante (también llamados inmunosupresores) como ciclosporina, sirolimus o tacrolimus.
English: Paroxetine/Emtricitabine
Spanish: Paroxetina/Emtricitabina
English: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26)
Spanish: AUC: ↑ 11% (↑ 5 a ↑ 18) Cmax: ↑ 16% (↑ 6 a ↑ 26) Cmin: ↑ 13% (↑ 1 a ↑ 26)
English: Atripla and sofosbuvir can be co-administered without dose adjustment.
Spanish: Atripla y sofosbuvir pueden coadministrarse sin ajuste de dosis.
English: Atovaquone and proguanil hydrochloride/Efavirenz (250/100 mg single dose/600 mg q.d.)
Spanish: Atovacuona y clorhidrato de proguanil/Efavirenz (dosis única de 250/100 mg/600 mg c/24 h)
English: AUC: ↓ 35% (↓ 13 to ↓ 40) Cmax: ↓ 13% (↓ 0 to ↓ 23)
Spanish: AUC: ↓ 35% (↓ 13 a ↓ 40) Cmax: ↓ 13% (↓ 0 a ↓ 23)
English: AUC: ↓ 69% (↓ 62 to ↓ 73) Cmax: ↓ 76% (↓ 63 to ↓ 79)
Spanish: AUC: ↓ 69% (↓ 62 a ↓ 73) Cmax: ↓ 76% (↓ 63 a ↓ 79)
English: Efavirenz/emtricitabine/tenofovir disoproxil
Spanish: Efavirenz/emtricitabina/tenofovir disoproxilo
English: Artemether/Lumefantrine/Tenofovir disoproxil
Spanish: Arteméter/Lumefantrina/Tenofovir disoproxilo
English: - You must remain under the care of your doctor while taking Atripla.
Spanish: - Mientras esté tomando Atripla debe permanecer bajo la vigilancia de su médico.
English: Clarithromycin/Emtricitabine
Spanish: Claritromicina/Emtricitabina
English: If serum phosphate is < 1.5 mg/dl (0.48 mmol/l) or creatinine clearance is decreased to < 50 ml/min in any patient receiving Atripla, renal function must be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Spanish: La evaluación de la función renal ha de repetirse tras una semana, incluyendo niveles de concentración de glucosa, potasio en sangre y glucosa en orina (ver sección 4.8, tubulopatía proximal) si el valor del fosfato sérico es < 1,5 mg/dl (0,48 mmol/l) o el aclaramiento de creatinina disminuye a < 50 ml/min en cualquier paciente que reciba Atripla.
English: Selective Serotonin Reuptake Inhibitors (SSRIs) Sertraline/Efavirenz (50 mg q.d./600 mg q.d.)
Spanish: Inhibidores selectivos de la recaptación de serotonina (ISRS) Sertralina/Efavirenz (50 mg c/24 h/600 mg c/24 h)
English: AUC12h: ↓ 45% (↓ 38 to ↓ 51) Cmax: ↓ 51% (↓ 37 to ↓ 62)
Spanish: AUC12h: ↓ 45% (↓ 38 a ↓ 51) Cmax: ↓ 51% (↓ 37 a ↓ 62)
English: Methadone/Emtricitabine
Spanish: Metadona/Emtricitabina
English: Prior NNRTI-based regimen (N=104)
Spanish: Pauta previa basada en ITINN (N = 104)
English: Co-administration of simeprevir with Atripla is not recommended.
Spanish: No se recomienda la administración concomitante de simeprevir con Atripla.
English: AUC: ↑ 98% (↑ 77 to ↑ 123) Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑ 197)
Spanish: AUC: ↑ 98% (↑ 77 a ↑ 123) Cmax: ↑ 79% (↑ 56 a ↑ 104) Cmin: ↑ 163% (↑ 137 a ↑ 197)
English: Atripla and vigabatrin or gabapentin can be coadministered without dose adjustment.
Spanish: Atripla y vigabatrina o gabapentina pueden administrarse concomitantemente sin ajustar la dosis.
English: (CYP3A4 induction).
Spanish: (inducción CYP3A4).
English: AUC: ↓ 71% (↓ 67 to ↓ 74) Cmax: ↓ 51% (↓ 46 to ↓ 56) Cmin: ↓ 91% (↓ 88 to ↓ 92)
Spanish: AUC: ↓ 71% (↓ 67 a ↓ 74) Cmax: ↓ 51% (↓ 46 a ↓ 56) Cmin: ↓ 91% (↓ 88 a ↓ 92)
English: Ear and labyrinth disorders: Uncommon tinnitus, vertigo
Spanish: Trastornos del oído y del laberinto: Poco frecuentes acúfenos, vértigo
English: AUC: ↓ 4% (↓ 0 to ↓ 31) Cmax: ↓ 47% (↓ 9 to ↓ 51)
Spanish: AUC: ↓ 4% (↓ 0 a ↓ 31) Cmax: ↓ 47% (↓ 9 a ↓ 51)
English: Reproductive system and breast disorders: Uncommon gynaecomastia
Spanish: Trastornos del aparato reproductor y de la mama: Poco frecuentes ginecomastia
English: Values for Test and Reference are mean (% coefficient of variation).
Spanish: Los valores de prueba y de referencia son la media (% coeficiente de variación) GMR = razón media geométrica de mínimos cuadrados, IC = intervalo de confianza
English: Tacrolimus/Emtricitabine/Tenofovir disoproxil (0.1 mg/kg q.d./200 mg/245 mg q.d.)
Spanish: Tacrolimus/Emtricitabina/ Tenofovir disoproxilo (0,1 mg/kg c/24 h/200 mg/245 mg c/24 h)
English: AUC: ↑ 81% (↑ 68 to ↑ 94) Cmax: ↑ 77% (↑ 53 to ↑ 104) Cmin: ↑ 121% (↑ 100 to ↑ 143)
Spanish: AUC: ↑ 81% (↑ 68 a ↑ 94) Cmax: ↑ 77% (↑ 53 a ↑ 104) Cmin: ↑ 121% (↑ 100 a ↑ 143)
English: Didanosine/Efavirenz
Spanish: Didanosina/Efavirenz
English: Atripla and raltegravir can be co-administered without dose adjustment.
Spanish: Atripla y raltegravir pueden coadministrarse sin ajuste de dosis.
English: AUC: ↓ 58% (↓ 39 to ↓ 68) Cmax: ↓ 51% (↓ 32 to ↓ 58)
Spanish: AUC: ↓ 58% (↓ 39 a ↓ 68) Cmax: ↓ 51% (↓ 32 a ↓ 58)
English: Voriconazole/Emtricitabine
Spanish: Voriconazol/Emtricitabina
English: AUC: ↓ 39% (↓ 30 to ↓ 46) Cmax: ↓ 26% (↓ 15 to ↓ 35)
Spanish: AUC: ↓ 39% (↓ 30 a ↓ 46) Cmax: ↓ 26% (↓ 15 a ↓ 35)
English: AUC: ↓ 60% (↓ 52 to ↓ 68) Cmax: ↓ 62% (↓ 55 to ↓ 78)
Spanish: AUC: ↓ 60% (↓ 52 a ↓ 68) Cmax: ↓ 62% (↓ 55 a ↓ 78)
English: Liver disease
Spanish: Enfermedad hepática
English: • decreased sexual drive
Spanish: • pérdida del apetito sexual
English: Efavirenz non-competitively inhibits HIV-1 reverse transcriptase (RT) and does not significantly inhibit human immunodeficiency virus-2 (HIV-2) RT or cellular deoxyribonucleic acid (DNA) polymerases (α, β, γ, and δ).
Spanish: Efavirenz inhibe no competitivamente la transcriptasa inversa (TI) del VIH-1 y no inhibe de manera significativa la TI del virus de la inmunodeficiencia humana-2
English: AUC: ↓ 52% (↓ 33 to ↓ 66) Cmax: ↓ 45% (↓ 25 to ↓ 59)
Spanish: AUC: ↓ 52% (↓ 33 a ↓ 66) Cmax: ↓ 45% (↓ 25 a ↓ 59)
English: Indinavir/Tenofovir disoproxil (800 mg q8h/245 mg q.d.)
Spanish: Indinavir/Tenofovir disoproxilo (800 mg c/8 h/245 mg c/24 h)
English: AUC: ↓ 75% (↓ 62 to ↓ 84) Cmax: ↓ 44% (↓ 20 to ↓ 61)
Spanish: AUC: ↓ 75% (↓ 62 a ↓ 84) Cmax: ↓ 44% (↓ 20 a ↓ 61)
English: Posaconazole/Emtricitabine
Spanish: Posaconazol/Emtricitabina
English: Atripla and fosamprenavir/ritonavir can be co-administered without dose adjustment.
Spanish: Atripla y fosamprenavir/ritonavir pueden coadministrarse sin ajuste de dosis.
English: AUC: ↓ 83% Cmax: ↓ 87%
Spanish: AUC: ↓ 83 % Cmáx: ↓ 87 %
English: Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together.
Spanish: Cuando se toman juntos medicamentos que contienen tenofovir disoproxilo y didanosina, se han comunicado en raras ocasiones inflamación del páncreas y acidosis láctica (exceso de ácido láctico en la sangre) en algunos casos mortales.
English: - any signs of skin rash.
Spanish: Cualquier signo de erupción cutánea.
English: - Medicines used to treat convulsions/seizures (anticonvulsants): Carbamazepine, phenytoin,
Spanish: (anticonvulsivantes): carbamazepina, fenitoína, fenobarbital.
English: Saquinavir/ritonavir/Emtricitabine
Spanish: Saquinavir/ritonavir/Emtricitabina
English: AUC: ↓ 39% (↓ 21 to ↓ 53) Cmax: ↓ 37% (↓ 20 to ↓ 51) Cmin: ↓ 44% (↓ 27 to ↓ 58)
Spanish: AUC: ↓ 39% (↓ 21 a ↓ 53) Cmax: ↓ 37% (↓ 20 a ↓ 51) Cmin: ↓ 44% (↓ 27 a ↓ 58)
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Spanish: Los pacientes con insuficiencia renal moderada o grave requieren un ajuste del intervalo de dosis de emtricitabina y tenofovir disoproxilo que no pueden conseguirse con el comprimido de combinación (ver las secciones 4.2 y 4.4).
English: Patients with moderate or severe renal impairment require a dose adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Spanish: Los pacientes con insuficiencia renal moderada o grave requieren un ajuste de dosis de emtricitabina y tenofovir disoproxilo que no puede obtenerse con el comprimido de combinación (ver las secciones 4.2 y 5.2).
English: The following side effects are rare (these may affect up to 1 in every 1,000 patients):
Spanish: Los siguientes efectos adversos son raros (estos pueden afectar hasta 1 de cada 1.000 pacientes):
English: Efavirenz concentrations not measured, no effect is expected.
Spanish: Concentraciones de efavirenz no medidas.
English: Saquinavir/ritonavir/Tenofovir disoproxil There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with ritonavir boosted saquinavir.
Spanish: No hubo interacciones farmacocinéticas clínicamente significativas cuando se coadministró tenofovir disoproxilo con saquinavir potenciado con ritonavir.
English: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Spanish: Se han notificado casos de osteonecrosis, especialmente en pacientes con infección avanzada por el VIH y/o exposición prolongada a la TARC, aunque se considera que la etiología es multifactorial (incluyendo uso de corticosteroides, consumo de alcohol, inmunodepresión grave, índice de masa corporal elevado).
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Spanish: Los pacientes con insuficiencia renal moderada o grave requieren un ajuste del intervalo de dosis de emtricitabina y tenofovir disoproxilo que no puede conseguirse con el comprimido de combinación (ver las secciones 4.4 y 5.2).
English: Ritonavir/Emtricitabine
Spanish: Ritonavir/Emtricitabina
English: AUC: ↓ 69% (↓ 55 to ↓ 79) Cmax: ↓ 60% (↓ 50 to ↓ 68) Cmin: ↓ 63% (↓ 44 to ↓ 75)
Spanish: AUC: ↓ 69% (↓ 55 a ↓ 79) Cmax: ↓ 60% (↓ 50 a ↓ 68) Cmin: ↓ 63% (↓ 44 a ↓ 75)
English: LIPID LOWERING MEDICINAL PRODUCTS HMG Co-A Reductase Inhibitors Atorvastatin/Efavirenz (10 mg q.d./600 mg q.d.)
Spanish: MEDICAMENTOS REDUCTORES DE LOS LÍPIDOS Inhibidores de la HMG-CoA reductasa Atorvastatina/Efavirenz (10 mg c/24 h/600 mg c/24 h)
English: - if you are taking other medicines that contain efavirenz, emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil.
Spanish: tenofovir disoproxilo, tenofovir alafenamida, lamivudina o adefovir dipivoxil.
English: Itraconazole/Emtricitabine
Spanish: Itraconazol/Emtricitabina
English: Co-administration of lopinavir/ritonavir and Atripla is not recommended.
Spanish: No se recomienda la administración concomitante de lopinavir/ritonavir y Atripla.
English: Methadone/Tenofovir disoproxil (40-110 mg q.d./245 mg q.d.)
Spanish: Metadona/Tenofovir disoproxilo (40-110 mg c/24 h/245 mg c/24 h)
English: AUC: ↓ 64% (↓ 62 to ↓ 67) Cmax: ↓ 46% (↓ 39 to ↓ 52) Cmin: ↓ 82% (↓ 79 to ↓ 85)
Spanish: AUC: ↓ 64% (↓ 62 a ↓ 67) Cmax: ↓ 46% (↓ 39 a ↓ 52) Cmin: ↓ 82% (↓ 79 a ↓ 85)
English: AUC: ↓ 34% (↓ 21 to ↓ 41) Cmax: ↓ 20% (↓ 2 to ↓ 26)
Spanish: AUC: ↓ 34% (↓ 21 a ↓ 41) Cmax: ↓ 20% (↓ 2 a ↓ 26)
English: Atazanavir/ritonavir/Emtricitabine
Spanish: Atazanavir/ritonavir/Emtricitabina
English: BOTTLE AND CARTON LABELLING
Spanish: TEXTO DE LA ETIQUETA DEL FRASCO Y DEL EMBALAJE EXTERIOR
English: Bupropion/Emtricitabine
Spanish: Bupropión/Emtricitabina
English: AUC: ↓ 43% (↓ 34 to ↓ 50) Cmax: ↓ 12% (↓ 1 to ↓ 26)
Spanish: AUC: ↓ 43% (↓ 34 a ↓ 50) Cmax: ↓ 12% (↓ 1 a ↓ 26)
English: Vigabatrin/Tenofovir disoproxil Gabapentin/Tenofovir disoproxil
Spanish: Vigabatrina/Tenofovir disoproxilo Gabapentina/Tenofovir disoproxilo
English: St. John's wort (Hypericum perforatum): Co-administration of Atripla and St. John's wort or herbal preparations containing St. John's wort is contraindicated.
Spanish: Hipérico (Hypericum perforatum): la administración concomitante de Atripla e Hipérico o medicamentos a base de plantas conteniendo Hipérico está contraindicada.
English: AUC: ↓ 55% (↓ 48 to ↓ 62) Cmax: ↓ 34% (↓ 21 to ↓ 47)
Spanish: AUC: ↓ 55% (↓ 48 a ↓ 62) Cmax: ↓ 34% (↓ 21 a ↓ 47)
English: Indinavir/Emtricitabine (800 mg q8h/200 mg q.d.)
Spanish: Indinavir/Emtricitabina (800 mg c/8 h/200 mg c/24 h)
English: AUC: ↓ 37% (↓ 14 to ↓ 55) Cmax: ↓ 35% (↓ 12 to ↓ 52) Cmin: ↓ 43% (↓ 18 to ↓ 60)
Spanish: AUC: ↓ 37% (↓ 14 a ↓ 55) Cmax: ↓ 35% (↓ 12 a ↓ 52) Cmin: ↓ 43% (↓ 18 a ↓ 60)
English: AUC: ↓ 27% (↓ 20 to ↓ 33) Cmax: ↓ 20% (↓ 15 to ↓ 24) Cmin: ↓ 35% (↓ 24 to ↓ 44)
Spanish: AUC: ↓ 27% (↓ 20 a ↓ 33) Cmax: ↓ 20% (↓ 15 a ↓ 24) Cmin: ↓ 35% (↓ 24 a ↓ 44)
English: Boceprevir/Efavirenz (800 mg q8h/600 mg q.d.)
Spanish: Boceprevir/Efavirenz (800 mg c/8 h/600 mg c/24 h)
English: AUC: ↓ 36% (↓ 32 to ↓ 40) Cmax: ↓ 21% (↓ 15 to ↓ 26) Cmin: ↓ 47% (↓ 41 to ↓ 53)
Spanish: AUC: ↓ 36% (↓ 32 a ↓ 40) Cmax: ↓ 21% (↓ 15 a ↓ 26) Cmin: ↓ 47% (↓ 41 a ↓ 53)
English: The following side effects are very common (these may affect more than 1 in 10 patients)
Spanish: Los siguientes efectos adversos son muy frecuentes (estos pueden afectar a más de 1 de cada 10 pacientes):
English: (CYP3A4 induction)
Spanish: (inducción de CYP3A4)
English: AUC: ↓ 39% (↓ 27 to ↓ 50) Cmax: ↓ 29% (↓ 15 to ↓ 40) Cmin: ↓ 46% (↓ 31 to ↓ 58)
Spanish: AUC: ↓ 39% (↓ 27 a ↓ 50) Cmax: ↓ 29% (↓ 15 a ↓ 40) Cmin: ↓ 46% (↓ 31 a ↓ 58)
English: Simeprevir/Efavirenz (150 mg q.d./600 mg q.d.)
Spanish: Simeprevir/Efavirenz (150 mg c/24 h/600 mg c/24 h)
English: AUC: ↓ 38% (↓ 28 to ↓ 47) Cmax: ↓ 32% (↓ 15 to ↓ 46) Cmin: ↓ 45% (↓ 31 to ↓ 56)
Spanish: AUC: ↓ 38% (↓ 28 a ↓ 47) Cmax: ↓ 32% (↓ 15 a ↓ 46) Cmin: ↓ 45% (↓ 31 a ↓ 56)
English: Darunavir/ritonavir/Emtricitabine
Spanish: Darunavir/ritonavir/Emtricitabina
English: Simeprevir/Tenofovir disoproxil (150 mg q.d./245 mg q.d.)
Spanish: Simeprevir/Tenofovir disoproxilo (150 mg c/24 h/245 mg c/24 h)
English: Atovaquone and proguanil hydrochloride/Tenofovir disoproxil
Spanish: Atovacuona y clorhidrato de proguanil/Tenofovir disoproxilo
English: Dose adjustments of diltiazem when coadministered with Atripla should be guided by clinical response (refer to the Summary of Product Characteristics for diltiazem).
Spanish: Cuando se administra concomitantemente con Atripla, los ajustes de la dosis de diltiazem deberán realizarse según la respuesta clínica (ver Ficha Técnica o Resumen de las Características del Producto para diltiazem).
English: Lopinavir/ritonavir tablets/Efavirenz (400/100 mg b.i.d./600 mg q.d.)
Spanish: Lopinavir/ritonavir comprimidos/ Efavirenz (400/100 mg c/12 h/600 mg c/24 h)
English: Methadone/Efavirenz (35-100 mg q.d./600 mg q.d.)
Spanish: Metadona/Efavirenz (35-100 mg c/24 h/600 mg c/24 h)
English: The following side effects are uncommon (these may affect up to 1 in every 100 patients):
Spanish: Los siguientes efectos adversos son poco frecuentes (estos pueden afectar hasta 1 de cada 100 pacientes):
English: AUC: ↓ 26% (↓ 15 to ↓ 36) Cmax: ↓ 20% (↓ 11 to ↓ 28) Cmin: ↓ 32% (↓ 15 to ↓ 46)
Spanish: AUC: ↓ 26% (↓ 15 a ↓ 36) Cmax: ↓ 20% (↓ 11 a ↓ 28) Cmin: ↓ 32% (↓ 15 a ↓ 46)
English: Sertraline/Tenofovir disoproxil
Spanish: Sertralina/Tenofovir disoproxilo
English: A similar reduction in indinavir exposures was observed when indinavir 1,000 mg q8h was given with efavirenz 600 mg q.d.
Spanish: Se observó una reducción similar en la exposición a indinavir cuando se administraron 1.000 mg de indinavir c/8 h con 600 mg de efavirenz c/24 h. (inducción de CYP3A4) Para la administración concomitante de efavirenz con una dosis baja de ritonavir en combinación con un inhibidor de la proteasa, ver la sección sobre ritonavir, más abajo.
English: If Atripla is stopped your doctor may recommend that you resume hepatitis B treatment.
Spanish: Si suspende el tratamiento con Atripla su médico puede recomendarle que reanude el tratamiento de la hepatitis B. Usted puede necesitar análisis de sangre para comprobar el funcionamiento del hígado durante cuatro meses tras suspender el tratamiento.
English: Fosamprenavir/ritonavir/Tenofovir disoproxil
Spanish: Fosamprenavir/ritonavir/Tenofovir disoproxilo
English: The pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Spanish: No se ha estudiado la farmacocinética de Atripla en pacientes con insuficiencia hepática.
English: Buprenorphine/naloxone/Tenofovir disoproxil
Spanish: Buprenorfina/naloxona/ Tenofovir disoproxilo
English: Morning AUC: ↑ 18% (↑ 6 to ↑ 33) Evening AUC: ↔ Morning Cmax: ↑ 24% (↑ 12 to ↑ 38)
Spanish: AUC matutina: ↑ 18% (↑ 6 a ↑ 33) AUC nocturna: ↔ Cmax matutina: ↑ 24% (↑ 12 a ↑ 38) Cmax nocturna: ↔ Cmin matutina: ↑ 42% (↑ 9 a ↑ 86) Cmin nocturna: ↑ 24% (↑ 3 a ↑ 50)
English: Fluoxetine/Tenofovir disoproxil
Spanish: Fluoxetina/Tenofovir disoproxilo
English: Rifabutin/Emtricitabine
Spanish: Rifabutina/Emtricitabina
English: Atripla and fluoxetine can be co-administered without dose adjustment.
Spanish: Atripla y fluoxetina pueden administrarse concomitantemente sin ajustar la dosis.
English: Lopinavir/ritonavir/Emtricitabine
Spanish: Lopinavir/ritonavir/Emtricitabina
English: Indinavir/Efavirenz (800 mg q8h/200 mg q.d.)
Spanish: Indinavir/Efavirenz (800 mg c/8 h/200 mg c/24 h)
English: Co-administration of atazanavir/ritonavir and Atripla is not recommended.
Spanish: No se recomienda la administración concomitante de atazanavir/ritonavir y Atripla.
English: Fosamprenavir/ritonavir/Emtricitabine
Spanish: Fosamprenavir/ritonavir/ Emtricitabina
English: Your doctor may need to consider giving you a different antifungal.
Spanish: Puede que su médico tenga que plantearse administrarle un antimicótico diferente.
English: Valproic acid/Tenofovir disoproxil
Spanish: Ácido valproico/Tenofovir disoproxilo
English: Ritonavir/Tenofovir disoproxil
Spanish: Ritonavir/Tenofovir disoproxilo
English: • breast enlargement in males
Spanish: • aumento de las mamas en los varones